Brazikumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Brazikumab
Monoclonal antibody
Type Whole antibody
Source Human
Target IL23
Clinical data
Synonyms MEDI2070
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6410H9830N1718O2016S50
Molar mass 144.8 kDa

Brazikumab (MEDI2070) (INN) is a human monoclonal antibody designed for the treatment of Crohn's disease.[1][2]

This drug was developed by MedImmune.

References[edit]